Prot #MCC-001: Phase 2 Study of aNK (Activated NK-92, Natural Killer Cells) Infusions in Combination with ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)

Project: Research project

Project Details

StatusActive
Effective start/end date3/10/173/10/23

Funding

  • NantKwest, Inc. (Prot #MCC-001)